A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models

Blood

Volumn 121, Issue 11, 2013, Pages 2108-2116

  Stennicke, Henning R ^a   Kjalke, Marianne ^a   Karpf, Ditte M ^a   Balling, Kristoffer W ^a   Johansen, Peter B ^a   Elm, Torben ^a   Øvlisen, Kristine ^a   Möller, Flemming ^a   Holmberg, Heidi L ^a   Gudme, Charlotte N ^a   Persson, Egon ^a   Hilden, Ida ^a   Pelzer, Hermann ^a   Rahbek Nielsen, Henrik ^a   Jespersgaard, Christina ^a   Bogsnes, Are ^a   Pedersen, Anette A ^a   Kristensen, Anne K ^a   Peschke, Bernd ^a   Kappers, Wendy ^a   Rode, Frederik ^a   Thim, Lars ^a   Tranholm, Mikael ^a   Ezban, Mirella ^a   Olsen, Eva H N ^a   Bjørn, Søren E ^a   more..

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCAN; MACROGOL; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBIN; VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 8; MACROGOL DERIVATIVE; N8 GP COMPOUND; N8-GP COMPOUND;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; CONTROLLED STUDY; DENDRITIC CELL; DRUG BINDING; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; HEMOPHILIA A; HUMAN; HUMAN CELL; IN VIVO STUDY; JOINT INJURY; MACACA FASCICULARIS; MALE; MEAN RESIDENCE TIME; MONOCYTE; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN DOMAIN; RAT; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; CELL CULTURE; CHO CELL; CRICETULUS; DISEASE MODEL; EVALUATION; FEMALE; GLYCOSYLATION; HAMSTER; METABOLISM; MOUSE MUTANT; PATHOLOGY; RABBIT; SPRAGUE DAWLEY RAT; TIME; TREATMENT OUTCOME;

ANIMALS; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; FACTOR VIII; FEMALE; GLYCOSYLATION; HEMOPHILIA A; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, BIOLOGICAL; POLYETHYLENE GLYCOLS; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84877623981     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-407494     Document Type: Article

References (36)

1. Coppola A, Di Capua M, De Simone C. Primary prophylaxis in children with haemophilia. Blood Transfus. 2008;6:(suppl 2):s4-s11.
2. Hay CR. Prophylaxis in adults with haemophilia. Haemophilia. 2007;13:(suppl 2):10-15.
3. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544.
4. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003; 2(3):214-221.
5. Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv. 2009;6(1):1-16.
6. Duncan R. Polymer therapeutics as nanomedicines: new perspectives. Curr Opin Biotechnol. 2011;22(4):492-501.
7. Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci. 2008;97(10): 4167-4183.
8. Mei B, Pan C, Jiang H, et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood. 2010;116(2): 270-279.
9. Schulte S. Pioneering designs for recombinant coagulation factors. Thromb Res. 2011;128:(suppl 1):S9-S12.
10. Dumont JA, Low SC, Peters RT, et al. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs. 2006;20(3):151-160.
11. Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood. 2012;119(13):3031-3037.
12. DeFrees S, Wang ZG, Xing R, et al. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology. 2006;16(9):833-843.
13. Stennicke HR, Ostergaard H, Bayer RJ, et al. Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives. Thromb Haemost. 2008;100(5):920-928.
14. Thim L, Vandahl B, Karlsson J, et al. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia. 2010;16(2):349-359.
15. Martinowitz U, Bjerre J, Brand B, et al. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) — an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Haemophilia. 2011;17(6):854-859.
16. van Haren SD, Wroblewska A, Fischer K, et al. Requirements for immune recognition and processing of factor VIII by antigen-presenting cells. Blood Rev. 2012;26(1):43-49.
17. Christensen S, Egebjerg J. Cloning, expression and characterization of a sialidase gene from Arthrobacter ureafaciens. Biotechnol Appl Biochem. 2005;41(pt 3):225-231.
18. Antuch W, Güntert P, Billeter M, et al. NMR solution structure of the recombinant tick anticoagulant protein (rTAP), a factor Xa inhibitor from the tick Ornithodoros moubata. FEBS Lett. 1994;352(2):251-257.
19. Lim-Wilby MS, Hallenga K, de Maeyer M, et al. NMR structure determination of tick anticoagulant peptide (TAP). Protein Sci. 1995;4(2):178-186.
20. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci USA. 1998;95(16):9524-9529.
21. Bi L, Sarkar R, Naas T, et al. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood. 1996;88(9):3446-3450.
22. Felo M, Defrees S. Nucleotide sugar purification using membranes. US patent WO2007056191. May 18, 2007.
23. Ovlisen K, Kristensen AT, Valentino LA, et al. Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice. J Thromb Haemost. 2008;6(6):969-975.
24. Christiansen ML, Balling KW, Persson E, et al. Functional characteristics of N8, a new recombinant FVIII. Haemophilia. 2010;16(6): 878-887.
25. Elm T, Karpf DM, Øvlisen K, et al. Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice. Haemophilia. 2012;18(1):139-145.
26. Møller F, Tranholm M. A ferric chloride induced arterial injury model used as haemostatic effect model. Haemophilia. 2010;16(1):e216-e222.
27. Uchida Y, Tsukada Y, Sugimori T. Enzymatic properties of neuraminidases from Arthrobacter ureafaciens. J Biochem. 1979;86(5):1573-1585.
28. Bovenschen N, Herz J, Grimbergen JM, et al. Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency. Blood. 2003;101(10):3933-3939.
29. Lenting PJ, Neels JG, van den Berg BM, et al. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. J Biol Chem. 1999;274(34):23734-23739.
30. Saenko EL, Yakhyaev AV, Mikhailenko I, et al. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. J Biol Chem. 1999;274(53):37685-37692.
31. Herczenik E, van Haren SD, Wroblewska A, et al. Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain. J Allergy Clin Immunol. 2012;129(2):501-509, 509.e1-e5.
32. Smolen J, Landewé RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009;68(6):797-804.
33. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood. 1996;88(8):2939-2950.
34. Appa RS, Oie CI, Kristensen JB, et al. GlycoPEGylation of FVIII reduces cellular uptake in the liver, but does not alter in vivo distribution. J Thromb Haemost. 2011;9:(suppl s2):567-568.
35. Dasgupta S, Repessé Y, Bayry J, et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood. 2007;109(2):610-612.
36. Wroblewska A, van Haren SD, Herczenik E, et al. Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice. Blood. 2012;119(22): 5294-5300.